drugset / Trial / NCT06947941

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

NCT06947941

Phase 3 Recruiting 325 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

Timeline

Start
2026-03-25
Primary completion
2028-02-21
Completion
2028-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject KarX-EC Unknown
Subject Trospium Small molecule